LXRX Phase III sotagliflozin HCM data expected in Q1 2027
LXRX expects key Phase III sotagliflozin data in HCM in Q1 2027, with commercial preparations underway. For T1D, an FDA resubmission is planned for Q4 as regulatory progress continues.
Key phase III data for sotagliflozin in HCM is expected in Q1 2027, with commercial preparations already under way and a focus on both obstructive and non-obstructive patient groups. Regulatory work in T1D is moving ahead with a Q4 FDA resubmission, while partnerships and AI initiatives are expected to expand p…